share_log

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

apellis pharmaceuticals宣布在纳斯达克5635(c)(4)条例下的诱导性发放。
GlobeNewswire ·  12/06 13:05

WALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of December 2, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

麻省沃尔瑟姆,2024年12月06日(环球新闻社) - 全球生物制药公司以及补体领域领先者Apellis Pharmaceuticals,Inc.(纳斯达克:APLS)今日宣布,公司批准向四名新员工授予股权奖励,授予日期为2024年12月2日,作为公司2017年股权激励计划之外的股权诱因奖励(但根据2020年诱因股权激励计划),对员工接受公司聘用具有重要意义。股权奖励已根据纳斯达克上市规则5635(c)(4)获得批准。

The employees received options to purchase 27,445 shares of Apellis' common stock and 28,630 restricted stock units (RSUs). The options have an exercise price of $35.42, which is equal to the closing price of Apellis' common stock on December 2, 2024, the grant date of the options. One-fourth of the shares underlying the employee options will vest on the one-year anniversary of the grant date and thereafter 1/48th of the shares underlying the employee options will vest monthly, such that the shares underlying the options granted to the employees will be fully vested on the fourth anniversary of the grant date, subject to the employees' continued employment with Apellis on such vesting dates. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date.

员工获得了购买Apellis普通股27,445股和28,630股有限制的股票单位(RSUs)的期权。这些期权的行权价为35.42美元,与2024年12月2日Apellis普通股的收盘价相等,即期权的授予日期。员工期权基础股份的四分之一将于授予日期的一周年日起获得,并且以后每月获得员工期权基础股份的四十八分之一,这样,授予员工的期权基础股份将在授予日期的第四周年日获得全部,前提是员工在这些获得日期继续在Apellis工作。每份RSU的基础股份将于授予日期的第一周年日获得25%,并在之后的每年连续获得25%,前提是每位员工在每个获得日期继续就业。

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.

关于Apellis
Apellis Pharmaceuticals是一家全球生物制药公司,结合勇敢的科学和同情心,为一些最具挑战性的疾病患者开发改变生命的治疗方案。我们推出了15年来第一个新的补体药物系,现有两种针对C3的批准药物,其中包括全球首款用于地理萎缩症的治疗。我们相信,我们才刚刚开始释放针对C3治疗严重眼部、罕见和神经系统疾病的潜力。欲了解更多信息,请访问或关注我们的Twitter和LinkedIn。

Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding plans to submit applications for regulatory approval for the treatment of patients with C3G and IC-MPGN. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether systemic pegcetacoplan will receive approval for those indications from the FDA or equivalent foreign regulatory agencies when expected or at all; and any other factors discussed in the "Risk Factors" section of Apellis' Annual Report on Form 10-K with the Securities and Exchange Commission on February 27, 2024 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Apellis前瞻性声明
本新闻稿中关于未来期望,计划和前景的声明,以及关于其他未成为历史事实的事项的任何其他声明,可能构成1995年《私人证券诉讼改革法》的"前瞻性声明"。这些声明包括但不限于有关申请治疗C3G和IC-MPGN患者的监管批准计划。

Media Contact:
Tracy Vineis
media@apellis.com
617-420-4839

媒体联系:
Tracy Vineis
media@apellis.com
617-420-4839

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

投资者联系人:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发